Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment

Pirisi, Mario; Fabris, Carlo; Soardo, G.; Cecchin, E; Toniutto, Pierluigi; Bartoli, Ettore

doi:10.1016/0168-8278(95)80342-4

Cited by 10 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect might be mediated through the increased risk of blood loss and haemoglobin drop in thrombocytopenic patients or the close association with thrombocytopenia and liver dysfunction rather than a direct regulatory pathway involving platelet counts or platelet turnover. Accordingly, a small study reported a beneficial role of short-term EPO administration in thrombocytopenic liver disease patients (36).…”

Section: Discussionmentioning

confidence: 99%

Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease

Tacke

Schöffski

Luedde

et al. 2004

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease

Tacke

Schöffski

Luedde

et al. 2004

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Based on these findings, erythropoietin [22] or newer TPO agonists, i.e. AMG531 currently in phase 2 clinical trial [23], could have a role in the management of platelet disorders in end-stage liver disease [12,[24][25][26][27][28][29].…”

Section: Discussionmentioning

confidence: 99%

Acute thrombocytopenia after liver transplant: Role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment

Nascimbene¹,

Iannacone²,

Brando³

et al. 2007

Journal of Hepatology

View full text Add to dashboard Cite

“…Treatment with exogenous erythropoietic stimulating agents (ESA) can also increase platelet count (10, 11); epoetin has even been used therapeutically to treat thrombocytopenia (12–14). ESA therapy is well known to induce a functional iron deficiency (or iron‐restricted erythropoiesis) in which increased erythron iron requirements exceed the available supply.…”

mentioning

confidence: 99%

Editorial Focus: Thrombosis with Erythropoietic Stimulating Agents—Does Iron‐Deficient Erythropoiesis Play a Role?

Dahl

Henry

Coyne

2008

Seminars in Dialysis

View full text Add to dashboard Cite

Thrombocytosis is common in iron deficiency and resolves following iron repletion. Increased platelet number, whether from iron deficiency or from other causes, may increase the risk of thrombovascular events. One mechanism thought to mediate iron deficiency-induced thrombocytosis is increased erythropoietin production. Similarly, erythropoietic stimulating agents (ESA) have long been known to increase platelet number and frequently lead to functional or absolute iron deficiency. This state of relative or absolute iron deficiency may be the mechanism whereby ESA increase the platelet count. If correct, co-administration of iron should prevent or diminish ESA-driven thrombocytosis. Data from the DRIVE trial in hemodialysis patients do, in fact, suggest that this is the case. Platelet counts in patients receiving IV iron decreased, while they remained unchanged in patients not given iron (mean change -29,000/microl vs. -0/microl; p = 0.017). Other supporting data have been observed in IV iron trials in oncology patients. The harm from higher hemoglobin targets and higher ESA doses may be mediated in part through induction of iron deficiency and thrombocytosis. The major anemia trials of ESAs have not reported platelet data, but should examine the relationship of platelet count, iron deficiency, IV iron administration, and cardiovascular events in greater detail.

show abstract

Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment

Cited by 10 publications

References 5 publications

Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease

Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease

Acute thrombocytopenia after liver transplant: Role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment

Editorial Focus: Thrombosis with Erythropoietic Stimulating Agents—Does Iron‐Deficient Erythropoiesis Play a Role?

Contact Info

Product

Resources

About